argenx (ARGX) to Release Earnings on Thursday

argenx (NASDAQ:ARGX - Get Free Report) is scheduled to release its earnings data before the market opens on Thursday, October 31st. Analysts expect argenx to post earnings of $0.10 per share for the quarter.

argenx (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, July 25th. The company reported $0.45 EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $1.34. The company had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same quarter last year, the company earned ($1.69) earnings per share. On average, analysts expect argenx to post $0 EPS for the current fiscal year and $5 EPS for the next fiscal year.

argenx Price Performance

ARGX traded down $6.77 during midday trading on Thursday, reaching $551.15. 99,779 shares of the company's stock were exchanged, compared to its average volume of 308,607. The business's 50-day moving average price is $534.21 and its 200 day moving average price is $458.10. argenx has a 1-year low of $327.73 and a 1-year high of $571.97. The stock has a market capitalization of $32.76 billion, a PE ratio of -97.38 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. Citigroup lifted their price target on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a report on Thursday, October 17th. Robert W. Baird lifted their target price on argenx from $490.00 to $515.00 and gave the stock an "outperform" rating in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "buy" rating to a "hold" rating in a research note on Friday, October 4th. Barclays upgraded shares of argenx from an "equal weight" rating to an "overweight" rating in a research note on Tuesday, August 6th. Finally, Evercore ISI raised their price target on argenx from $478.00 to $533.00 and gave the stock an "outperform" rating in a report on Friday, July 12th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, argenx presently has a consensus rating of "Moderate Buy" and a consensus target price of $550.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.